The biogenic amine histamine is an important pharmacological mediator involved in pathophysiological processes such as allergies and inflammations. Histamine H 1 receptor (H 1 R) antagonists are very effective drugs alleviating the symptoms of allergic reactions. Here we show the crystal structure of the H 1 R complex with doxepin, a first-generation H 1 R antagonist. Doxepin sits deep in the ligand-binding pocket and directly interacts with Trp 428 6.48 , a highly conserved key residue in G-protein-coupled-receptor activation. This well-conserved pocket with mostly hydrophobic nature contributes to the low selectivity of the first-generation compounds. The pocket is associated with an anion-binding region occupied by a phosphate ion. Docking of various second-generation H 1 R antagonists reveals that the unique carboxyl group present in this class of compounds interacts with Lys 191 5.39 and/or Lys 179 ECL2
The biogenic amine histamine is an important pharmacological mediator involved in pathophysiological processes such as allergies and inflammations. Histamine H 1 receptor (H 1 R) antagonists are very effective drugs alleviating the symptoms of allergic reactions. Here we show the crystal structure of the H 1 R complex with doxepin, a first-generation H 1 R antagonist. Doxepin sits deep in the ligand-binding pocket and directly interacts with Trp 428 6.48 , a highly conserved key residue in G-protein-coupled-receptor activation. This well-conserved pocket with mostly hydrophobic nature contributes to the low selectivity of the first-generation compounds. The pocket is associated with an anion-binding region occupied by a phosphate ion. Docking of various second-generation H 1 R antagonists reveals that the unique carboxyl group present in this class of compounds interacts with Lys 191 5.39 and/or Lys 179
ECL2
, both of which form part of the anion-binding region. This region is not conserved in other aminergic receptors, demonstrating how minor differences in receptors lead to pronounced selectivity differences with small molecules. Our study sheds light on the molecular basis of H 1 R antagonist specificity against H 1 R.
Histamine is a biogenic amine and an important mediator in various physiological and pathophysiological conditions such as arousal state, allergy and inflammation [1] [2] [3] . Histamine exerts its effects through the activation of four distinct histamine receptors (H 1 , H 2 , H 3 and H 4 ) that belong to the G-protein-coupled-receptor (GPCR) superfamily. The H 1 R, originally cloned from bovine H 1 R 4 , is now known to be expressed in various human tissues including airway, intestinal and vascular smooth muscle and brain 2 . In type I hypersensitivity allergic reactions, H 1 R is activated by histamine released from mast cells, which are stimulated by various antigens 5 . Many studies have been performed to develop H 1 R antagonists, known generally as antihistamines. Many of these compounds inhibit the action of histamine on H 1 R to alleviate the symptoms of allergic reactions, making H 1 R one of the most validated drug targets judging from the number of drugs approved 6 . H 1 R shows constitutive activity, and H 1 R antagonists generally act as inverse agonists for H 1 R 7,8 . Development of H 1 R antagonists has progressed through two generations. First-generation drugs such as pyrilamine and doxepin ( Supplementary Fig. 1 ) are effective H 1 R antagonists. These compounds are, however, known to show considerable side effects such as sedation, dry mouth and arrhythmia, because of penetration across the blood-brain barrier and low receptor selectivity. These H 1 R antagonists can bind not only to H 1 R but also to other aminergic GPCRs, monoamine transporters and cardiac ion channels. Second-generation drugs such as cetirizine and olopatadine ( Supplementary Fig. 1 ) are less sedating and in general have fewer side effects. The improved pharmacology of the secondgeneration zwitterionic drugs can be attributed to a new carboxylic moiety, in combination with the protonated amine, which significantly reduces brain permeability, although residual central nervous system effects are still reported 9 . The introduction of the carboxyl moiety also improves the H 1 R selectivity of these compounds, but certain secondgeneration H 1 R antagonists-such as terfenadine-still show cardiotoxicity because of their interaction with cardiac potassium channels 10, 11 . A first-generation H 1 R antagonist, doxepin, can cause many types of side effects due to its antagonistic effects on histamine H 2 (ref. 12), serotonin 5-HT 2 , a 1 -adrenergic, and muscarinic acetylcholine receptors 13 in addition to the inhibition of the reuptake of serotonin and noradrenaline 14 . Although even raw homology models of GPCRs may facilitate discovery of novel ligands 15, 16 , reliable receptor structures are essential to improve the reliability of the predictions and understand the structural basis of subtype specificity. Recently determined GPCR structures have enabled structure-based approaches to modelling ligand interactions in the binding pocket [17] [18] [19] [20] [21] [22] [23] and are already yielding novel chemotypes predicted by virtual screening of large chemical libraries 24, 25 . Here we report the 3.1 Å resolution structure of the H 1 R-T4-lysozyme fusion protein (H 1 R-T4L) complex with doxepin. The crystal structure reveals the atomic details of doxepin binding and its inverse agonistic activity. The H 1 R crystal structure and models of second-generation H 1 R antagonists will be highly beneficial for guiding rational design of ligands that do not penetrate the blood-brain barrier while maintaining H 1 selectivity.
Overall architecture of H 1 R
In the H 1 R construct, T4L 26 was inserted into the third cytoplasmic loop (intracellular loop 3 (ICL3)) (Gln 222-Gly 404) and 19 residues were truncated from the amino-terminal region (Met 1-Lys 19) (see Methods). H 1 R-T4L showed similar binding affinities for H 1 R antagonists and for histamine as the wild-type H 1 R expressed in yeast cells (Supplementary Table 1 ) and in COS-7 cells 27 . The structure of the H 1 R-T4L crystals obtained in the lipidic cubic phase (see Methods) was determined in complex with the H 1 R antagonist doxepin at 3.1 Å resolution (Supplementary Table 2 ).
H 1 R is structurally most similar to the aminergic receptors ( Fig. 1 ): b 2 -adrenergic (b 2 -AR) 18 , b 1 -adrenergic (b 1 -AR) 19 and dopamine D3 (D3R) 23 receptors, while having larger deviations from the more phylogenetically distant rhodopsin 17, 21 , A 2A adenosine receptor (A 2A AR) 20 and chemokine receptor CXCR4 (ref. 22) (Supplementary Table 3 ). H 1 R also shares common motifs with other GPCRs including D(E)RY in helix III, CWxP in helix VI and NPxxY in helix VII, as well as a disulphide bond connecting extracellular loop 2 (ECL2) with the extracellular end of helix III (Cys 100 3.25 to Cys 180; superscripts indicate residue numbers as per the Ballesteros-Weinstein scheme 28 ) but lacks the palmitoylation site at the end of helix VIII found in many other GPCRs 29 . Previous GPCR structures revealed that not only the residues in the transmembrane segments but also those in the loops are critical for ligand specificity [17] [18] [19] [20] [21] [22] [23] . ECL2 connecting helices IV and V is attached to helix III through a disulphide bond between Cys 180 in ECL2 and Cys 100 3.25 in helix III. Seven residues (Phe 168-Val 174) before the disulphide are not included in the structure, as they did not have interpretable densities. A section of ECL2, between the disulphide bridge and the extracellular end of helix V, is particularly important because it is located at the entrance to the ligand-binding pocket. This section of ECL2 contains 7 amino acids in H 1 R, as compared to 5 in b 2 -AR, 4 in D3R, and 8 in A 2A AR. The extra length of this ECL2 section is apparently accommodated by the increased distance between the extracellular ends of helices III and V by ,1.5 Å and ,3.1 Å when compared to b 2 -AR and D3R, respectively (Fig. 1b, c) . This creates more space within the ligand-binding pocket, which can now accommodate the larger second-generation H 1 R antagonists, as discussed later.
Some unique features are also observed in the transmembrane segments. A conserved Pro 161 4.59 -induced kink in helix IV forms a tight i13 helical turn, instead of i14 as in b 2 -AR and D3R (Fig. 2a) . This tighter turn allows accommodation of a bulky Trp side chain at position 4.56, which seems to be essential for ligand specificity of aminergic GPCRs because this position is occupied by Ser in b 2 6.36 in helix VI (Fig. 2b) . Different structures of the ionic lock regions of the receptors could be caused by modifications of ICL3. Otherwise, they might be related to the different levels of constitutive activities of the receptors.
Doxepin isomers and conformers
The doxepin used in this study contains a mixture of E and Z isomers, and each isomer can take two distinct rotational conformers of the dibenzo[b,e]oxepin ring, resulting in four distinct conformers (conformers 1-4; Supplementary Fig. 2 ). Two conformers, one E isomer (conformer 1) and one Z isomer (conformer 4), fit the electron density better than the other two ( Supplementary Fig. 3 ). This result is also consistent with the R free and the averaged B-factor values for each conformer (Supplementary Table 4 , which forms a hydrogen bond with Arg 125 3.50 , is also shown. Possible hydrogen bonds are indicated by dotted lines.
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with the binding pocket; consequently, in the following sections we are referring to the E isomer, unless noted otherwise.
Ligand-binding pocket
Doxepin binds in a pocket mainly defined by the side chains of helices III, V and VI (Fig. 3a, b) . Asp 107 3.32 , a strictly conserved residue in aminergic receptors (Supplementary Table 5 ), forms an anchor salt bridge with the amine moiety of the ligand. This interaction has been reported to be essential for the binding of H 1 R antagonists as well as agonists in mutational studies [31] [32] [33] . This amine moiety is connected via a flexible carbon chain to the tricyclic dibenzo[b,e]oxepin ring in a hydrophobic pocket comprised of the side chains of helices III, V and VI. The tricyclic ring of doxepin sits much deeper (by ,5 Å ) in the binding pocket than the ligands in the other non-rhodopsin GPCR structures (Fig. 3c) 5.46 in the pocket make only minor hydrophobic interactions with doxepin (Fig. 3a, b) . The importance of a large side chain at position 6.52 has been suggested for the binding of pyrilamine 30, 33 . Thr 112 3.37 can form a hydrogen bond to the oxygen atom of the E isomer (but not the Z isomer) of doxepin, as shown in Fig. 3a , b. A suboptimal geometry and the bifurcated nature of this hydrogen bond indicate that it does not contribute significantly to binding affinity, which is supported by lack of this hydrogen-bond interaction in the H 1 R-olopatadine complex, as described later. This well-conserved pocket and its mostly hydrophobic nature should contribute to low selectivity of doxepin and other first-generation H 1 R-antagonists 13, 32 . Moreover, because of its deep binding position, doxepin does not interact with ECL2, whose highly variable primary and tertiary structures are known to contribute to binding specificity of GPCR ligands 34 . A novel feature of the H 1 R-doxepin complex is the existence of an anion-binding site at the entrance to the ligand-binding pocket (Fig. 3d) . We modelled a phosphate ion, which is present at a high concentration in the crystallization buffer (300 mM ammonium phosphate), into the observed strong density in the site. This model is supported by the fact that a phosphate ion affects the binding of some ligands and the stability of H 1 R (Supplementary Tables 1 and 6 
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indicating its physiological relevance. The affinity of histamine and pyrilamine to the receptors also increased in the presence of phosphate.
H 1 selectivity of H 1 R antagonists
Supplementary Fig. 1 lists the first and second generations of H 1 R antagonists. It has been shown that second-generation H 1 R antagonists are much more specific to H 1 R and show much lower affinity to the other aminergic receptors 32, 35 . H 1 R-antagonist specificity has been previously analysed using H 1 R-homology models based on the bacteriorhodopsin or bovine rhodopsin crystal structure in combination with the H 1 R antagonist pharmacophore model and mutational studies 30, 36, 37 . These studies have successfully determined some residues important for selectivity, including Lys 191 5.39 ; however, contributions of the ECL residues have not been examined because these loops could not be modelled accurately based on the bacteriorhodopsin or bovine rhodopsin structure. Our H 1 R structure with the extracellular loops should significantly improve understanding of H 1 R-antagonist selectivity. Using flexible ligand-receptor docking 38, 39 in the ICM molecular modelling package 40 (also see Methods), we have studied H 1 R selectivity for representative second-generation zwitterionic H 1 R-antagonists: olopatadine, acrivastine, R-cetirizine (levocetirizine) and fexofenadine (Fig. 4) . Olopatadine (Fig. 4a) is a close doxepin analogue with a methyl-carboxyl substitution in one of its benzene rings. Its binding mode closely resembles doxepin, while the carboxyl group extends out of the pocket towards the extracellular space and interacts with Lys 191 5.39 and Tyr 108 3.33 without displacing the phosphate ion. These additional interactions can explain a reduced effect of the mutation of the conserved Asp 107 3.32 to Ala on olopatadine binding (14-fold for olopatadine as compared to 280-fold for doxepin) 32, 41 . The orientation of the carboxyl moiety in the ECL region dictates that the oxygen atom of the dibenzo[b,e]oxepin ring is in a position where it cannot form a hydrogen bond with Thr 112 3.37 . Although the marketed drug is only the Z isomer, both olopatadine Z and E isomers show similar H 1 R affinities 41 . Acrivastin (Fig. 4b) has a different chemical scaffold with a carboxyl group in its pyridine ring. Its longer carbon chain positions the carboxyl group higher in the ECL region, where it can form salt bridges to both Lys 191 5.39 and Lys 179 ECL2 amine moieties. R-cetirizine (Fig. 4c) 
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which reaches outside of the binding cavity and forms a salt bridge to Lys 191 5.39 . Modelling of second-generation H 1 R-antagonist binding to H 1 R indicates that no significant protein backbone rearrangements are required to accommodate these diverse ligands. The enhanced H 1 R selectivity of these compounds 32, 35 can be explained by the specific interaction of the carboxyl group with Lys residues in the ECL region, unique to H 1 R. The result also shows a good agreement with earlier modelling and site-directed mutagenesis studies. Lys 191 5 .39 is known to be important for increasing affinity for some of these ligands 30, 42, 43 , whereas the involvement of Lys 179 ECL2 was suggested in the modelling study of 8R-lisuride into the ligand-binding pocket 44 . Our modelling results also indicate that olopatadine is the only second-generation compound studied here for which the carboxyl moiety does not interfere with phosphate binding. The results are also supported by the fact that the presence of the phosphate ion increased the thermal stability of the H 1 R-doxepin or H 1 R-olopatadine complexes, whereas it did not affect the stability of the H 1 R-cetirizine complex (Supplementary Table 6 ).
Mechanism of H 1 R inactivation
H 1 R antagonists act as highly effective inverse agonists of H 1 R, which reduce basal activity of the receptor and therefore are expected to interfere with the key molecular switches involved in the GPCR activation mechanism. One of the switches is represented by Trp 6.48 of the conserved CWxP 6.50 motif, which helps to stabilize rhodopsin in its inactive dark state through a direct interaction with retinal. The recently published structure of the active-state A 2A AR 45 also showed that Trp 6.48 participates in the activation-related conformational changes, where a small ligand-induced shift of Trp 6.48 was observed in concert with the large movement of the intracellular part of helix VI. In other receptors, the role of Trp 6.48 is less obvious; for instance, it lacks direct ligand interactions with either inverse agonists or full agonists of b 2 -AR 46 . It is interesting to note that in the H 1 R structure, like in inactive rhodopsin, the H 1 R-antagonist doxepin does make extensive hydrophobic interactions with the Trp 428 6.48 rings, which is unique among the known non-rhodopsin GPCR structures and could stabilize the hydrophobic packing around helix VI (Fig. 3c) . Another important ligand-induced switch described in b 2 -AR is activation-related contraction of the extracellular ligand-binding pocket 37 . Because the natural agonist histamine is much smaller than bulky H 1 R antagonists, some contraction of the binding pocket is likely to accompany ligand-induced H 1 R activation. Bulky compounds, capable of blocking both activation-related contraction of the pocket and the Trp 428 6.48 switch would be very efficient in locking H 1 R in an inactive conformation, which is likely to explain the as much as 78% reduction of H 1 R basal activity by some H 1 R antagonists 8 .
METHODS SUMMARY
H 1 R-T4L was expressed in yeast Pichia pastoris. Ligand-binding assays were performed as described in Methods. P. pastoris membranes were solubilized using 1% (w/v) n-dodecyl-B-D-maltopyranoside and 0.2% (w/v) cholesteryl hemisuccinate, and purified by immobilized metal ion affinity chromatography (IMAC). After IMAC, the C-terminal GFP was cleaved by Tobacco Etch virus (TEV) protease. Then the sample mixture was passed through IMAC to remove the cleaved His-tagged GFP and TEV protease. Receptor crystallization was performed by the lipidic cubic phase (LCP) method. The protein-LCP mixture contained 40% (w/w) receptor solution, 54% (w/w) monoolein, and 6% (w/w) cholesterol. Crystals were grown in 40-50 nl protein-laden LCP boluses overlaid by 0.8 ml of precipitant solution (26-30% (v/v) PEG400, 300 mM ammonium phosphate, 10 mM MgCl 2 , 100 mM Na-citrate pH 4.5 and 1 mM doxepin) at 20 uC. Crystals were harvested directly from LCP matrix and flash frozen in liquid nitrogen. X-ray diffraction data were collected at 100 K with a beam size of 10 3 10 mm on the microfocus beamline I24 at the Diamond Light Source (UK). Data collection, processing, structure solution and refinement are described in Methods. Supplementary Information is linked to the online version of the paper at www.nature.com/nature.
METHODS
Construction of the H 1 R expression vectors for Pichia pastoris. The coding sequence of the full-length human histamine H 1 receptor (H 1 R-fl), in which N-linked glycosylation sites (Asn 5 and Asn 18) were mutated to glutamines, was synthesized with optimization of codon usage for P. pastoris (TAKARA Bio), and cloned into the pPIC9K expression vector (Invitrogen). The H 1 R-T4L construct with an N-terminal 19-residue deletion and insertion of cysteine-less (C54T, C97A) T4 lysozyme into the third intracellular loop was generated by the yeast homologous recombination technique in Saccharomyces cerevisiae with the SmaI linearized plasmid pDDGFP2 (ref. 47 ) and three PCR products with ,30 bp overlapping sequences. The three fragments were individually generated by standard PCR techniques with the indicated primers. The generated plasmid integrating H 1 R-T4L followed by TEV cleavage sequence (ENLYFQG), yeast enhanced GFP and octa-histidine tag (H 1 R-T4L-GFP) was isolated from S. cerevisiae. Coding regions of the H 1 R-T4L-GFP fusions were amplified by PCR using a forward primer containing a BamHI site (59-CTAGAACTAGTGGATCCACCATG-39) and a reverse primer containing an EcoRI site (59-GCTTGATATCGAATTCCTGCAGTTAATG-39). The PCR products were digested with BamHI and EcoRI, and subcloned into the pPIC9K vector.
Expression and membrane preparation. The PmeI linearized pPIC9K expression vector integrating H 1 R-fl-GFP or H 1 R-T4L-GFP was then transformed into the P. pastoris SMD1163 strain by electroporation (2,000 V, 25 mF, and 600 V) using a Gene Pulser I (Bio-Rad). Clone selection was performed on the YPD-agar plate containing 0. Yeast cells were disrupted with 0.5 mm glass beads in a buffer containing 50 mM HEPES, pH 7.5, 120 mM NaCl, 5%(v/v) glycerol, 2 mM EDTA and EDTA-free protein inhibitor cocktail (Roche). Undisrupted cells and cell debris were separated by centrifugation at 3,000g, and yeast membranes were collected by ultracentrifugation at 100,000g for 30 min at 4 uC. Washing of the membranes was performed by repeating dounce homogenation and centrifugation in a high salt buffer containing 10 mM HEPES, pH 7.5, 1 M NaCl, 10 mM MgCl 2 , 20 mM KCl and EDTA-free protease inhibitor cocktail. Prepared membranes were resuspended in a buffer containing 50 mM HEPES pH 7.5, 120 mM NaCl, 20% (v/v) glycerol and EDTA-free protease inhibitor cocktail, and snap-frozen in liquid nitrogen and stored at 280 uC until use. Membrane proteins were quantified using the bicinchoninic acid method (Pierce). Purification of H 1 R-T4L. Membrane suspension containing H 1 R-T4L-GFP was thawed and incubated on ice for 30 min in the presence of 5 mM doxepin, 10 mg ml 21 iodoacetamide, and EDTA-free protease inhibitor cocktail (Roche). The membrane suspension was poured into the buffer containing 20 mM HEPES pH 7.5, 500 mM NaCl, 1% (w/v) n-dodecyl-B-D-maltopyranoside (DDM, Anatrace), 0.2% (w/v) cholesteryl hemisuccinate (CHS, Sigma), 20% (v/v) glycerol and 2-3 mg ml 21 membrane, and stirred gently at 4 uC for 1-2 h. The unsolubilized material was separated by centrifugation at 100,000g for 30 min. The supernatant was incubated with TALON IMAC resin (Clontech) overnight. The resin was washed with twenty column volumes of 20 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol, 0.025% (w/v) DDM, 0.005% (w/v) CHS, 100 mM doxepin and 20 mM imidazole. The protein was eluted with 4 column volumes of 20 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol, 0.025% (w/v) DDM, 0.005% (w/v) CHS, 500 mM doxepin and 200 mM imidazole. The eluted fractions were concentrated to 2.5 ml with a 100 kDa molecular weight cut-off AmiconUltra (Millipore). Imidazole was removed using PD-10 column (GE healthcare). Then the protein was loaded onto the Ni-Sepharose high performance resin (GE healthcare) (1.5 ml resin for ,10 mg of protein). The resin was washed with 20 column volumes of 20 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol, 0.025% (w/v) DDM, 0.005% (w/v) CHS, 500 mM doxepin and 20 mM imidazole. The sample was eluted with 3 column volumes of 20 mM HEPES pH 7.5, 500 mM NaCl, 10% glycerol, 0.025% (w/v) DDM, 0.005% (w/v) CHS, 1 mM doxepin and 500 mM imidazole. Imidazole was removed using PD-10 column (GE healthcare). The protein was processed overnight with His-tagged TEV protease (expressed and purified in house). TEV protease and the cleaved His-tagged GFP were removed by passing the sample through the Ni-Sepharose high performance resin. The receptor was concentrated to 30-40 mg ml 21 with a 100 kDa molecular weight cut-off Vivaspin concentrator (Vivascience). Protein purity and monodispersity were tested by SDS-PAGE and by size-exclusion chromatography using Superdex 200 (GE healthcare). Lipidic cubic phase crystallization. Lipidic cubic phase (LCP) crystallization trials were performed using an in meso crystallization robot as previously described 48 . Ninety-six-well glass sandwich plates were filled with 40-50 nl protein-laden LCP boluses overlaid by 0.8 ml of precipitant solution in each well and sealed with a glass coverslip. The protein-LCP mixture contained 40% (w/w) receptor solution, 54% (w/w) monoolein, and 6% (w/w) cholesterol. Crystallization set-ups were performed at room temperature (20-22 uC) . Plates were incubated and imaged at 20 uC using an automated incubator/imager (RockImager 1000, Formulatrix). Crystals were obtained in 26-30% (v/v) PEG400, 300 mM ammonium phosphate, 10 mM MgCl 2 , 100 mM Na-citrate pH 4.5 and 1 mM doxepin (Sigma) (Supplementary Fig. 4 ). Crystals were harvested directly from LCP matrix using MiTeGen micromounts and were flash-frozen in liquid nitrogen without additional cryoprotectant.
Data collection and refinement. X-ray diffraction data were collected at 100 K with a wavelength of 0.97780 Å and with a beamsize of 10 3 10 mm on the microfocus beamline I24 at the Diamond Light Source (UK) with a Pilatus 6M detector. Each loop was subjected to a grid scanning 49 in order to locate the crystals, which are invisible in the LCP once they are mounted. The exact locations and dimensions of the chosen crystals were determined by further grid scanning with a smaller search area. Data collection was carried out by collecting several overlapping wedges of data from adjacent positions within a single crystal. The data were processed initially with xia2 50 using Mosflm 51 and Scala 52 with the merging statistics used to determine an optimum subset of measurements to merge. The final data set consisted of data from five of the eight positions recorded, giving a total of 75 degrees of data. These data were then remerged with Scala to give the final data set summarized in Supplementary Table 2. The space group was determined to be I422 with one molecule in the asymmetric unit. Diffraction data were slightly anisotropic, extending to 2.9 Å in the c* direction and to 3.1 Å in the a* and b* directions. The structure factors up to 3.1 Å resolution were anisotropically scaled by PHASER 53 and then used for the subsequent molecular replacement and refinement. The structure was determined by molecular replacement with the program PHASER 53 using two independent search models (polyalanine of the 7 transmembrane a-helices, and T4L) from the b 2 -AR (PDB code 2RH1) structure. We chose b 2 -AR as a model structure because it has the highest homology of transmembrane helices with H 1 R (41.7%) among the human GPCR structures. For the initial map calculation after molecular replacement, however, we used a b 2 -AR model without side chains, loops, ligand, lipids and any solvents; therefore, the final H 1 R structure is not biased to the b 2 -AR structure. This is supported by low R work and R free values (Supplementary Table 2 ). All refinements were performed with REFMAC5 54 and autoBUSTER 55 followed by manual examination and rebuilding of the refined coordinates in the program Coot 56 . The non-lysozyme portion contains higher B factors (116 Å 2 ) owing to fewer contacts as compared to T4 lysozyme (36 Å 2 ). Calculation of the surface area buried by crystal contacts also explains this. For the non-lysozyme portion, only 8% (1,225 Å 2 ) of 15,689 Å 2 solvent-accessible surface area is buried by crystal contacts. In contrast, for the T4 lysozyme portion, 32% (2,733 Å 2 ) of the solvent accessible area (8,648 Å 2 ) is buried by crystal interactions. Supplementary Fig. 5 also shows that there are strong interactions between T4 lysozyme domains, but relatively fewer between non-lysozyme domains throughout the crystal packing. Although the average B factor of the non-lysozyme domain is high as compared to T4 lysozyme, electron densities were clear for unambiguous model building (Supplementary Figs 3 and 5) . The eight H 1 R N-terminal residues (Thr 20-Leu 27), two C-terminal residues (Arg 486-Ser 487), and seven residues (Phe 168-Val 174) in the second extracellular loop (ECL2) are not included in the structure, as they did not have interpretable densities.
Strong and spherical electron densities (about 4 sigma) were found in the anion-binding region in the F o 2 F c omit map. We excluded the presence of a water molecule in this region owing to strong residual positive F o 2 F c densities when we modelled it as a water molecule. The coordination geometry in the highly electropositive environment surrounded by His 450 7.35 , Lys 179 ECL2 and Lys 191 5.39 implied that either a phosphate or sulphate ion could be modelled. Because ammonium phosphate was added to our crystallization buffer, we modelled it as a phosphate ion. The average B factors of the phosphate ion and the interacting atoms are 177 Å 2 
